Description
Indications
Mirdametinib is the first and only therapy approved in the European Union for adults and children 2 years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
How It Works
Mirdametinib How It Works How It Works ,
Dosage
2 GOMEKLI 2 mg/m², , , 28 21 GOMEKLI (2) 2.1 GOMEKLI GOMEKLI [ Precautions (5.1)] (EF)[ Precautions (5.2)] 2.2 GOMEKLI GOMEKLI GOMEKLI ,
Precautions
5 Precautions GOMEKLI , , , , GOMEKLI (5.1) GOMEKLI , , 3 , GOMEKLI (5.2) , , GOMEKLI


